Hee-jin Ha

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Discovery of a Novel Multitarget Analgesic Through an In Vivo-Guided Approach.

Discovery of a Novel Multitarget Analgesic Through an In Vivo-Guided Approach.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 26, 2024

Discovery of Dual TRPA1 and TRPV1 Antagonists as Novel Therapeutic Agents for Pain.

Discovery of Dual TRPA1 and TRPV1 Antagonists as Novel Therapeutic Agents for Pain.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: July 23, 2024

Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain.

Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 30, 2023

Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents.

Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents.

Journal: European journal of medicinal chemistry
Published: August 02, 2022

Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.

Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.

Journal: European journal of medicinal chemistry
Published: July 19, 2021

Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift.

Discovery of Benzopyridone-Based Transient Receptor Potential Vanilloid 1 Agonists and Antagonists and the Structural Elucidation of Their Activity Shift.

Journal: Journal of medicinal chemistry
Published: January 01, 2021

O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer's disease by inhibiting necroptosis.

O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer's disease by inhibiting necroptosis.

Journal: Science advances
Published: June 14, 2020

Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.

Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.

Journal: Journal of medicinal chemistry
Published: November 09, 2019

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design.

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design.

Journal: Journal of medicinal chemistry
Published: August 15, 2019

Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors.

Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors.

Journal: Bioorganic & medicinal chemistry
Published: March 27, 2018

Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.

Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.

Journal: Bioorganic & medicinal chemistry
Published: January 02, 2018

Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease.

Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease.

Journal: Journal of medicinal chemistry
Published: November 22, 2017
Showing 1-12 of 19

Last Updated: 09/26/2026